An Urgent Call for Transformation: Prescribers Need Better Information and a Streamlined Specialty Prescribing Process

May 21, 2019

Most likely, you or someone you love has been impacted by a complex or chronic illness like cancer or multiple sclerosis. Sadly, these diseases—and the cost of medications to treat them—are on the rise. More than half of specialty drugs cost in excess of $100,000 a year. As a result, spending on branded specialty medications is rising by 10 percent a year and is projected to surpass half of all medication spending by 2022, even though these drugs comprise just a fraction of all prescribed medications.

Naturally, healthcare providers want to start patients on their chosen medication therapies immediately. Yet they’re too often met with friction that can unnecessarily protract the specialty prescribing timeframe.

In fact, less than one-third of prescribers are either extremely or very satisfied with the efficiency of their organization’s current prescribing process. And according to our recent survey of 500 prescribers and our new data brief Provider Perspectives on Specialty Prescribing, when prescribers run into roadblocks along the way, nearly 70 percent change or reroute their orders.

From treatment delays caused by prior authorization, to a lack of trustworthy patient information at the point of care, prescribers are calling for transformation. Most prescribers said they don’t have digital access to patient information about out-of-pocket cost, lower-cost alternatives, prior authorization requirements and specialty pharmacy locations. And anywhere from half to three-quarters of prescribers said they don’t trust the information that they get manually.

This is a real problem today, and one that could reach a crisis point within just a few years.

Beyond the disturbing macro trends, I put myself in the shoes of a newly diagnosed cancer patient. I can imagine the added turmoil of being forced to wait to start my treatment. Whether due to prior authorization or an out-of-pocket cost that I cannot afford, this would be a critical moment in my healthcare journey. So I would absolutely be counting on my provider to quickly complete the prior authorization process and have information about a potentially cheaper therapeutic alternative at her fingertips.

At Surescripts, our history, scale and experience guide us first to understand the problems prescribers and pharmacists are running into on the ground, and then layer on the tools that smooth the process and speed the time to start therapy.

In the coming weeks, look for a series of brief articles drilling down into the specific insights healthcare providers shared in our survey about their experience with the specialty prescribing process.

Related Articles

August 13, 2019

When Paperwork Comes Before Patients: Missing Key Information Complicates Specialty Prescribing

William J. Mayo, MD, (“Doctor Will”) said, “The best interest of the patient is the only interest to be considered, and in order that the sick may have the benefit of advancing knowledge, union of forces is necessary.”

July 25, 2019

How Aurora Health Care Used Electronic Prior Authorization To Cut Clinic Staff Overtime By More Than Half

The reality of traditional prior authorization is this: While the prescriber, the PBM and the pharmacy team spend valuable time making phone calls, tracking down information and filling out forms, the patient waits. And waits. And waits. In other words, patients face delays in receiving their prescriptions, clinicians lose valuable time and the health system faces mounting overtime costs.

July 22, 2019

The Onerous Specialty Prescribing Process Hurts Patients and Tires Doctors. What Can Be Done?

It really should be so simple—getting a patient on a specialty therapy. The doctor and patient have chosen the best therapy; the patient is in great need. But according to our recent survey of 500 prescribers, on average it can take nearly 8 days to start patients on specialty medications, which are used to treat challenging chronic conditions such as cancer, multiple sclerosis and rheumatoid arthritis.